FARMACOLOGÍA
DEPARTAMENTO
Hospital Universitario Virgen Macarena
Sevilla, EspañaPublicaciones en colaboración con investigadores/as de Hospital Universitario Virgen Macarena (26)
2024
-
Factors Contributing to Negative Outcomes Associated with Medications and Drug-Related Problems in Kidney Replacement Therapy—A Hospital-Based Prospective Observational Study
Journal of Clinical Medicine, Vol. 13, Núm. 4
2023
-
Clinical Outcomes of First-line Therapies for Advanced Non-Small Cell Lung Cancer: A Systematic Review of Trials Published Between 2010 and 2020
American journal of clinical oncology, Vol. 46, Núm. 10, pp. 433-438
-
Medication Review with Follow-Up for End-Stage Renal Disease: Drug-Related Problems and Negative Outcomes Associated with Medication—A Systematic Review
Journal of Clinical Medicine, Vol. 12, Núm. 15
2021
-
Analyzing the clinical benefit of newer therapies for advanced or metastatic non-small-cell lung cancer: application of the ESMO-magnitude of clinical benefit scale v1.1
Acta Oncologica, Vol. 60, Núm. 9, pp. 1225-1232
-
Association between polymorphisms in the vitamin D receptor and susceptibility to multiple sclerosis
Pharmacogenetics and Genomics, Vol. 31, Núm. 2, pp. 40-47
-
Genetic polymorphisms on the effectiveness or safety of breast cancer treatment: Clinical relevance and future perspectives
Mutation Research - Reviews in Mutation Research, Vol. 788
-
Impact of a risk-sharing agreement in rheumatoid arthritis in Spain
Health Policy, Vol. 125, Núm. 3, pp. 335-340
-
Pharmacogenetic Predictors of Response to Interferon Beta Therapy in Multiple Sclerosis
Molecular Neurobiology, Vol. 58, Núm. 9, pp. 4716-4726
-
Therapeutic value of single nucleotide polymorphisms on the efficacy of new therapies in patients with multiple sclerosis
Journal of Personalized Medicine, Vol. 11, Núm. 5
2020
-
Association of ABCB1 and VEGFA gene polymorphisms with breast cancer susceptibility and prognosis
Pathology Research and Practice, Vol. 216, Núm. 4
-
Effect of genetic polymorphisms on therapeutic response in multiple sclerosis relapsing-remitting patients treated with interferon-beta
Mutation Research - Reviews in Mutation Research, Vol. 785
-
Pharmacist recommendations for carbapenem de-escalation in urinary tract infection within an antimicrobial stewardship program
Journal of Infection and Public Health, Vol. 13, Núm. 4, pp. 558-563
-
Randomized, double-blind, controlled trial, phase III, to evaluate the use of platelet-rich plasma versus hyaluronic acid in hip coxarthrosis
Revista Espanola de Cirugia Ortopedica y Traumatologia, Vol. 64, Núm. 2, pp. 134-142
2019
-
A multicentre observational study of the effectiveness, safety and economic impact of nivolumab on non-small-cell lung cancer in real clinical practice
International Journal of Clinical Pharmacy, Vol. 41, Núm. 1, pp. 272-279
-
Clinical outcomes of carbapenem de-escalation regardless of microbiological results: A propensity score analysis
International Journal of Infectious Diseases, Vol. 85, pp. 80-87
-
Trends in endpoint selection and result interpretation in advanced non-small cell lung cancer clinical trials published between 2000 and 2012: A retrospective cohort study
Thoracic Cancer, Vol. 10, Núm. 4, pp. 904-908
2018
-
Hospital pharmacy and critical care medicine: A necessary alliance
Farmacia Hospitalaria
-
Hospital pharmacy and critical care medicine: A necessary alliance
Biomedical Instrumentation and Technology
-
Loss of efficacy and safety of the switch from infliximab original to infliximab biosimilar (CT-P13) in patients with inflammatory bowel disease
World Journal of Gastroenterology, Vol. 24, Núm. 46, pp. 5288-5296
-
Multi-criteria decision analysis as a decision-support tool for drug evaluation: A pilot study in a pharmacy and therapeutics committee setting
International Journal of Technology Assessment in Health Care, Vol. 34, Núm. 5, pp. 519-526